# Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

> **NCT02266537** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 97 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tamsulosin
- **DRUG:** Alfuzosin
- **DRUG:** Doxazosin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02266537
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2014-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02266537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02266537, "Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02266537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*